What is the date and time of the JPI seminar regarding the drug discovery ecosystem?

The seminar will be held on Thursday, April 09, 2026, from 09:30 to 11:30.

Who is the lecturer for this seminar from the Ministry of Health, Labour and Welfare?

The lecturer is Mr. Yasuhiro Araki, the Director of the Clinical Trial Promotion Office.

What does the term drug loss refer to according to the lecture overview?

It refers to the problem where medicines approved in Europe and the United States are not developed in Japan.

Is it possible to apply for the seminar after the live session has ended?

Yes, applications for archive streaming will be accepted even after the seminar has ended.

What are the three goals that the public and private sectors in Japan are working together to discuss?

They are strengthening Japan's drug discovery capabilities, rapidly delivering the latest medicines, and sustaining the cycle of investment and innovation.

AI News NQ Analysis

[JPI Seminar] Ministry of Health, Labour and Welfare "Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials" to be held on Thursday, April 9th

NQ Score 50/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the date and time of the JPI seminar regarding the drug discovery ecosystem?: A: The seminar will be held on Thursday, April 09, 2026, from 09:30 to 11:30.
Q: Who is the lecturer for this seminar from the Ministry of Health, Labour and Welfare?: A: The lecturer is Mr. Yasuhiro Araki, the Director of the Clinical Trial Promotion Office.
Q: What does the term drug loss refer to according to the lecture overview?: A: It refers to the problem where medicines approved in Europe and the United States are not developed in Japan.
Q: Is it possible to apply for the seminar after the live session has ended?: A: Yes, applications for archive streaming will be accepted even after the seminar has ended.
Q: What are the three goals that the public and private sectors in Japan are working together to discuss?: A: They are strengthening Japan's drug discovery capabilities, rapidly delivering the latest medicines, and sustaining the cycle of investment and innovation.